1. Generics Bulletin

Amgen Chooses To Settle In US Soliris IPR Tussle

Victory Could Have Led To 2022 Market Entry

 
• By Dean Rudge

Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

2025_Dial
A successful IPR challenge could have led Amgen to potential market entry in 2022 or 2023 • Source: Shutterstock

Amgen has reached a settlement with Alexion Pharmaceuticals in patent-litigation proceedings over Soliris (eculizumab), picking up the rights to launch Amgen’s ABP 959 eculizumab biosimilar in the US from 1 March 2025, around two years ahead of various Soliris patents expiring.

A filing with the US Securities and Exchange Commission reveals the firms have entered into a confidential settlement and license agreement that dissolves three inter partes review proceedings instituted in August last year at

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business